文献リスト

1) Hideshima T, Richardson PG, Chauhan D, et al. The protease inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001; 61: 3071-6

2) ベルケード. ヤンセンファーマ社適正使用ガイド(一部改), 2007

3) Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005; 352: 2487-98

4) Richardson PG, Sonneveld P, Schuster MW, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to- event results of the APEX trial. Blood. 2007; 110: 3557-60

5) San-Miguel JF, Richardson PG, Sonneveld P, et al. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia. 2008; 22: 842-9

6) Richardson PG, Sonneveld P, Schuster MW, et al. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol. 2007; 137: 429-35

7) Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of peglyated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007; 25: 3892-901

8) Richardson PG. Advanced multiple myeloma: New treatment paradigms and clinical insights. MMRF corporate Friday symposium: New clinical strategies and emerging research in multiple myeloma. Friday, December 3, 2004

9) Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomized controlled trial. Lancet. 2006; 367: 825-31

10) Palumbo A, Bringhen S, Liberati AM, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood. 2008; 112: 3107-14

11) Wijermans P, Schaafsma M, Termorshuizen F, et al. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: The HOVON 49 study. J Clin Oncol. 28: published ahead of print on June 1, 2010 as 10. 1200/JCO. 2009. 26. 1610

12) Dimopoulous MA, Spencer A, Attal M, et al. Multiple myeloma (010) study investigators. lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007: 357: 2123-32

13) Weber DM, Chen C, Niesvizky R, et al. Multiple myeloma(009)study investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in north America. N Engl J Med. 2007; 357: 2133-42

14) Harousseau JL, Attal M, Leleu X, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica. 2006; 91: 1498-505

15) Harousseau JL, Avet-Loiseau H, Attal M, et al. High complete and very good partial response rates with bortezomib-dexamethasone as induction prior to ASCT in newly diagnosed patients with high-risk myeloma: Results of the IFM 2005-01 Phase3 trial. Blood. 2009; 114(ASH Annual Meeting Abstracts #353)

16) San-Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008; 359: 906-17

17) Mateos MV, Richardson PG, Schlag R, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: Updated follow-up and impact of subsequent therapy in the Phase III VISTA trial. J Clin Oncol. 28: published ahead of print on April 5, 2010 as 10. 1200/JCO. 2009. 26. 0638

18) Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomized controlled trial. Lancet Oncol. 2010; 23: 29-37

19) Mitsiades N, Mitsiades CS, Poulki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: Therapeutic implications. Blood. 2002; 99: 4525-30

20) Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000; 96: 2943-50

21) Anderson KC, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma (MM): Final results of a multicenter phase I/II study. J Clin Oncol. 2010; 28 (577s) abstract # 8016

22) Cavo M, Tacchett P, Patriarca F, et al. A phase III study of double autotransplantation incorporating bortezomib-thalidomide-dexamethasone (VTD) or thalidomide-dexamethasone (TD) for multiple myeloma: Superior clinical outcomes with VTD compared with TD. Blood. 2009; 114(ASH Annual Meeting Abstracts #351)

23) Maeos MV, Oriol A, Martinez J, et al. A prospective, multicenter, randomized, trial of bortezomib/melphalan/prednisone (VMP) versus bortezomib /thalidomide/prednisone (VTP) as induction therapy followed by maintenance treatment with bortezomib/thalidomide (VT) versus bortezomib/prednisone (VP) in elderly untreated patients with multiple myeloma older than 65 years. Blood. 2009; 114(ASH Annual Meeting Abstract #3)

24) Palumbo A, Dimopoulos MA, Delforge M, et al. A phase III study to determine the efficacy and safety of lenalidomide in combination with melphalan and prednisone (MPR) in elderly patients with newly diagnosed multiple myeloma. Blood. 2009; 114(ASH Annual Meeting Abstract #613)

25) McCarthy PL, Owzar K, Anderson KC, et al. Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB100104. J Clin Oncol. 2010; 28 (577s) abstract # 8017

26) Attal M, Cristini C, Marit G, et al. Lenalidomide maintenance after transplantation for myeloma. J Clin Oncol. 2010; 28 (577s) abstract # 8018

27) 後藤明彦, 大屋敷一馬, 押味和夫, 他. 日本人における再発・難治性多発性骨髄腫に対する個人輸入ボルテゾミブ治療に関連した肺障害—日本血液学会・日本臨床血液学会アンケート調査に基づく｢ボルテゾミブ肺障害調査委員会｣よりのレポート—. 臨床血液. 2006; 47: 1521-7

28) Niesvisky R, Richardson PG, Rajkumar SV, et al. The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. Br J Haematol. 2008; 143: 46-53

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp